Sandoz Egypt Pharma and Ibnsina Pharma ink strategic partnership to improve patient access to OTC Products

Sandoz Egypt Pharma and Ibnsina Pharma ink strategic partnership to improve patient access to OTC Products

- Sandoz announced the launch of its portfolio of OTC products in the Egyptian market at the beginning of 2022

Cairo – Sandoz Egypt Pharma and Ibnsina Pharma have announced a distribution and promotion agreement for the Sandoz over-the-counter (OTC) portfolio of products, strengthening the company’s commitment to widening access to products, with the help of Ibnsina’s expansive nationwide network. The broad outlines of the agreement amplify both companies’ efforts to reach a higher number of underserved patients.

Sameh Elbagoury, General Manager at Sandoz Egypt and Libya, said: “OTC products are vital to advancing healthcare, and our partnership with a true market leader like Ibn Sina is an important step, catalyzing our ability on-ground to live up to our relentless commitment to improving access. Our OTC portfolio in Egypt currently spans eight products and we have concrete plans to expand, transforming it into one of our strategic pillars, alongside our generic and biosimilar drug portfolios.”

“By allowing people to recover from minor conditions like the common cold, allergies, minor pains and others, OTC products not only help people get back to enjoying their day-to-day lives faster, but they also help relieve the burden on the average citizen suffering from minimal symptoms, as well